PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Summary

The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.

Timeline

Start

2011-05-01

Primary completion

2011-10-01

Completion

2011-10-01

Outcome

Met primary endpoint

paper All GP MDI treatments were superior to placebo MDI for the primary efficacy endpoint (all p < 0.0001). PMID 29506504 ↗

Publications

• Kerwin EM, Spangenthal S, Kollar C, St Rose E, Reisner C. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD. Respir Res. 2018 Mar 5;19(1):38. doi: 10.1186/s12931-018-0739-6.

Drugs

Indications